Bacteremia in acute pyelonephritis in multicenter hospital-at-home care: incidence, risk factors, and outcomes
Bacteremia complicating acute pyelonephritis is associated with increased morbidity, yet data on outcomes in hospital-at-home (HaH) settings remain unknown. We aimed to evaluate risk factors and outcomes of bacteremia among patients with acute pyelonephritis managed in a HaH program across three U.S. regions. We conducted a retrospective multicenter study of adults treated for acute pyelonephritis in the Mayo Clinic Advanced Care at Home program in Florida, Wisconsin, and Arizona, from July 2020 to January 2026. The primary outcome was the development of bacteremia during hospitalization. Secondary outcomes included identification of risk factors for bacteremia. Multivariable logistic regression was used to identify independent predictors. Among 221 patients with acute pyelonephritis, 28.5% ( n = 63) developed bacteremia. Baseline demographics and comorbidity burden were similar between groups; however, patients with bacteremia had higher severity of illness and were more likely to present with sepsis and acute kidney injury. In multivariable analysis, hemodialysis (adjusted odds ratio [OR] 6.11, 95% confidence interval [CI] 1.79–24.95; P = 0.006) and sepsis (adjusted OR 3.42, 95% CI 1.66–7.14; P < 0.001) were associated with the highest odds of bacteremia, whereas indwelling urinary catheter use had borderline higher odds. Escherichia coli was the leading blood culture isolate (29 of 63, 46.0%), and changes in antimicrobial therapy were more often de-escalations (52 of 72, 72.2%) than escalations. Patients with bacteremia had a longer total length of stay and a longer HaH length of stay. There were no deaths in either group. In this U.S. multicenter study of patients with acute pyelonephritis managed in a HaH setting, bacteremia occurred in nearly one-third of patients and was primarily associated with acute illness severity and high-risk conditions rather than baseline comorbidity burden. Hemodialysis and sepsis were the strongest predictors of bacteremia. The absence of mortality across groups supports the safety of HaH for carefully selected patients with bacteremia. These findings provide insights for risk stratification and management of pyelonephritis and bacteremia in HaH programs.
Authors
- Aryan Shiari (ORCID: https://orcid.org/0000-0002-6707-5029)
- Sagar B. Dugani (ORCID: https://orcid.org/0000-0001-7858-1317)
- Wendelyn Bosch (ORCID: https://orcid.org/0000-0003-3021-2752)
- Igor Dumic (ORCID: https://orcid.org/0000-0002-5312-8812)
- Michael Maniaci
- Cesar Abraham Gomez Cabello
- Margaret Paulson
- Li Zhuo
Institutions
- Lahey Hospital and Medical Center (US)
- Mayo Clinic (US)
- Mayo Clinic Health System (US)
- Mayo Clinic in Florida (US)
Publication Details
- Journal
- BMC Infectious Diseases
- Published
- 2026-11-14
- DOI
- https://doi.org/10.1186/s12879-026-14788-0
- Primary Topic
- Urinary Tract Infections Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00